Hematologic responses of patients with sickle cell disease to treatment with hydroxyurea.
Because fetal hemoglobin contains gammaglobin chains instead of beta chains, it is not affected by the genetic defect that causes sickle cell disease. Increased levels of fetal hemoglobin decrease the tendency toward intracellular polymerization of sickle hemoglobin that characterizes this disease. Hydroxyurea is one of several cytostatic agents that have been shown to increase the production of fetal hemoglobin in some patients with sickle cell disease. We studied the effects of hydroxyurea administration in 10 hospitalized patients with sickle cell disease, each of whom was treated for three months. Seven patients responded with a 2- to 10-fold increase in fetal hemoglobin, from a mean (+/- SD) of 1.6 +/- 1.6 percent of total hemoglobin to 6.8 +/- 4.7 percent; three patients had fetal-hemoglobin levels of 10 to 15 percent of total hemoglobin. Three did not respond to treatment. Four of the patients who responded were retreated with hydroxyurea after one to four months without treatment and were found to have larger increases in fetal-hemoglobin levels. In most patients, levels were still rising at the end of the study, even after 90 days of therapy. Fetal-hemoglobin levels tended to peak at dosages of hydroxyurea that were myelosuppressive. In the patients who responded to treatment, there were significant increases in the percentage of reticulocytes and erythrocytes containing fetal hemoglobin and in the amount of fetal hemoglobin within these cells. The percentage of dense red cells decreased in the patients who responded to treatment. The tendency toward intracellular polymerization at physiologic oxygen saturation was reduced by about 33 percent in the cells containing fetal hemoglobin, whereas there was no change in the other cells. We conclude that hydroxyurea is effective in increasing the production of fetal hemoglobin, which in this study was found to be associated with a small decrease in hemolysis and an increase in hemoglobin levels despite myelosuppression. Controlled, prospective trials are necessary to establish whether these effects will lead to clinical benefit.
Rodgers
G P
GP
Laboratory of Chemical Biology, NIDDK, National Institutes of Health, Bethesda, MD 20892.
Dover
G J
GJ
Noguchi
C T
CT
Schechter
A N
AN
Nienhuis
A W
AW
D000328:Adult; D000755:Anemia, Sickle Cell / Q000097:blood* / Q000188:drug therapy; D001772:Blood Cell Count; D001853:Bone Marrow / Q000187:drug effects; D005260:Female; D005319:Fetal Hemoglobin / Q000032:analysis*; D006410:Hematopoiesis / Q000187:drug effects; D006451:Hemoglobin, Sickle / Q000378:metabolism; D006454:Hemoglobins / Q000032:analysis; D006801:Humans; D006918:Hydroxyurea / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D008297:Male; D011108:Polymers
D006451:Hemoglobin, Sickle; D006454:Hemoglobins; D011108:Polymers; D005319:Fetal Hemoglobin; D006918:Hydroxyurea